Hypertension Clinical Trials in Prague
14 recruitingPrague, Czechia
Showing 1–14 of 14 trials
Recruiting
Phase 3
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
Cardiovascular DiseasesHypertensionDiabetes Mellitus, Type 2
Boehringer Ingelheim11,800 enrolled1153 locationsNCT07064473
Recruiting
Not Applicable
BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT
HypertensionHypertension, SystolicHypertension,Essential
Orchestra BioMed, Inc500 enrolled98 locationsNCT06059638
Recruiting
Phase 3
LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2
Pulmonary Hypertension Associated With HFpEF
Tenax Therapeutics, Inc.540 enrolled92 locationsNCT07288398
Recruiting
Phase 3
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
Hypertension
Eli Lilly and Company974 enrolled101 locationsNCT06948422
Recruiting
Not Applicable
Novel Setup Algorithm for Cardiac Neuromodulation Therapy
HypertensionBradycardia
BackBeat Medical Inc30 enrolled7 locationsNCT05719454
Recruiting
Phase 3
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)
Pulmonary Arterial Hypertension
Merck Sharp & Dohme LLC815 enrolled63 locationsNCT07218029
Recruiting
Phase 1Phase 2
A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)
Healthy Volunteers, Pulmonary Arterial Hypertension
Novartis Pharmaceuticals232 enrolled29 locationsNCT06649110
Recruiting
Phase 3
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
Hypertension
Eli Lilly and Company487 enrolled99 locationsNCT06952530
Recruiting
Phase 3
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
HypertensionOverweight or Obesity
Eli Lilly and Company487 enrolled99 locationsNCT06948435
Recruiting
Phase 3
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
Chronic Kidney Disease and Hypertension
AstraZeneca5,000 enrolled753 locationsNCT06742723
Recruiting
Not Applicable
Hepatic Venous Pressure Gradient Versus Endoscopic Ultrasound-Guided Portal Pressure Gradient - Comparative Analysis (HEPCA)
CirrhosisPortal HypertensionNon-Cirrhotic Portal Hypertension+3 more
Military University Hospital, Prague40 enrolled2 locationsNCT07424963
Recruiting
Not Applicable
sFlt1/PlGF and Planned Delivery to Prevent Preeclampsia at Term.
PreeclampsiaIntrauterine Growth RestrictionMaternal Hypertension+2 more
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau9,132 enrolled21 locationsNCT04766866
Recruiting
Mechanisms of Pulmonary Vascular Dysfunction in Heart Failure
Heart FailurePulmonary HypertensionPulmonary Vascular Resistance Abnormality
Institute for Clinical and Experimental Medicine230 enrolled1 locationNCT06331208
Recruiting
Phase 4
Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I Patients
Pulmonary Arterial Hypertension
AOP Orphan Pharmaceuticals AG110 enrolled19 locationsNCT06317805